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Abstract
A significant feature of influenza pandemics is multiple waves of morbidity and mortality over a few months or years. The
size of these successive waves depends on intervention strategies including antivirals and vaccination, as well as the effects
of immunity gained from previous infection. However, the global vaccine manufacturing capacity is limited. Also, antiviral
stockpiles are costly and thus, are limited to very few countries. The combined effect of antivirals and vaccination in
successive waves of a pandemic has not been quantified. The effect of acquired immunity from vaccination and previous
infection has also not been characterized. In times of a pandemic threat countries must consider the effects of a limited
vaccine, limited antiviral use and the effects of prior immunity so as to adopt a pandemic strategy that will best aid the
population. We developed a mathematical model describing the first and second waves of an influenza pandemic including
drug therapy, vaccination and acquired immunity. The first wave model includes the use of antiviral drugs under different
treatment profiles. In the second wave model the effects of antivirals, vaccination and immunity gained from the first wave
are considered. The models are used to characterize the severity of infection in a population under different drug therapy
and vaccination strategies, as well as school closure, so that public health policies regarding future influenza pandemics are
better informed.
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Introduction
Influenza pandemics have been known to cause multiple waves
of morbidity and mortality over a few months or years [1]. The
cause of the wave behaviour of influenza pandemics is not
precisely understood [2,3]. Control measures such as vaccination
and antiviral drugs will have an effect [4,5], but to what extent do
these need to be used to protect a population from severe
infection? In June 2009, the World Health Organization declared
the new strain of swine-origin H1N1 as a pandemic. Several
countries combined antivirals and vaccinaiton strategies to battle
the first and second waves of this pandemic. It is unknown,
however, how effective these interventions have been on
decreasing infection. School closure for the summer term in many
countires may also have had an affect on disease spread. In this
paper we provide estimates on the efficacy of antivirals and
vaccination in the first and second waves of a pandemic, including
a scenario of school closure in the summer months.
Vaccination is used to induce immunity in individuals such that,
if they are exposed to the virus they have a high probability of
resisting infection. Vaccination can also benefit a population by
inducing herd immunity, where individuals that are not vaccinated
are still protected from infection. Vaccination is the mainstay of
seasonal influenza, however, in a pandemic situation the strain is
initially unknown and the vaccine can take several months to be
formulated. Thus, it is unlikely to be implemented in the first wave
of infection, and may be available early in the second wave.
However, the global manufacturing vaccine capacity is limited and
is unlikely to meet the full demand of a pandemic threat. Also, the
vaccine is developed from an early pandemic strain and if the
strain changes over time, because of the high mutation rate of
influenza, the vaccine will be less effective and only induce partial
immunity.
Since efficacious vaccines are unlikely to be widely available
during at least the first wave of pandemic influenza, antivirals,
which reduce the ability of the virus to replicate but not provide
immunity to a host, form a critical component for the containment
of a pandemic. Antivirals may aid in the prevention of infection,
but also reduce the severity of infection and the level of
transmission [5–8]. Potential roles for antivirals include post-
exposure prophylaxis (when drugs are given to individuals shortly
after they are exposed), pre-exposure prophylaxis (when drugs are
given before exposure) and early treatment (when drugs are given
shortly after symptoms are presented).
During the 2009 H1N1 pandemic, vaccination and antivirals
were employed to fight infection. Antivirals stockpiles of
oseltamivir (Tamiflu) and zanamivir (Relenza), which were
accumulated by many different countries in wait of the next
pandemic threat, were used to provide prophylaxis and treat
infections. In the beginning of the second wave, vaccination was
also available. The use of antivirals and the rate of vaccine uptake,
however, varied greatly by country (see Table 1). But, how do
different control strategies affect the waves of morbidity and
mortality of a pandemic?
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months. It has been shown that this can have substantial impact on
the spread of an infectious disease which is transmitted through
close contacts [9,10]. Along with the use of antivirals, school
closure must have had a great effect on disease spread in the first
wave. But, does school closure change the most effective control
strategy against a pandemic?
Mathematical modelling provides a toolkit that can be used to
evaluate different control strategies of antiviral use and vaccine
uptake, as well as school closure. Mathematical models have been
employed to measure the efficacy of mitigation strategies of
pandemic influenza considering pharmaceutical as well as non-
pharmaceutical interventions [11–16]. They also rationalized the
use of antiviral agents for both treatment and prophylaxis as a
primary control measures during early stages of a pandemic
[11,12]. Since the start of the H1N1 pandemic a number of
mathematical epidemiological studies have been used to under-
stand the pandemic potential of the novel H1N1 strain early on
[17], the initial transmission characteristics [18–20], and the
disease burden and societal costs associated with infection [21].
Recently, mathematical studies have been used to evaluate the
effects of a late release of a vaccine and closing schools [9,22,23]
and the prophylactic use of antivirals [24].
A drawback of previous models of pandemic influenza is that
they either ignore or do not explicitly consider the effects of
immunity acquired from the first wave on disease outcomes in the
second and consecutive waves. The underlying immunity of
individuals can have a profound impact on the prevalence of
disease in a population and the level of disease that is observed.
This is seen through the correlation of transmissibility and
immunity which are interlinked with the degree of susceptibility
and disease outcome [25]. We have developed a mathematical
model describing the first and second waves of an influenza
pandemic, including antivirals, vaccination and summer school
closure, that explicitly considers the effects of acquired immunity
from the first wave of infection. This explicit consideration will aid
in assessing pandemic control policies in a more informed manner.
Methods
The mathematical model is composed of two smaller mathe-
matical models describing the first and the second waves
respectively. In both models we consider the effects of antivirals
and/or vaccination that are available during that period. In the
first wave we also consider the effects of summer school closures,
and in the both waves we consider the effects of acquired
immunity from previous infection either of the pandemic strain, or
a seasonal influenza strain that may be closely related [26].
First wave
Assumptions and Initial Conditions. The mathematical
model of the first wave is an extension of an SEIR (susceptible-
exposed-infected-recovered) model that includes the use of
antivirals and the probability of asymptomatic infection.
Acquired immunity from previous infections of influenza that are
relatedtothecurrentcirculatingpandemicstrainmayhave aneffect
on the size of the first wave through the effects of partial immunity
[26]. It is, however, difficult to determine what percentage of the
population, if any, has been infected by a strain that is related to the
pandemic strain. It is also difficult to determine whether these
individuals still maintain any immunity acquired from this previous
infection. Since partial immunity may aid in preventing disease
(symptoms) we include an asymptomatic class (A) in the model.
Antivirals form a critical component for the containment of a
pandemic in the first wave. Antivirals may reduce the ability of the
virus to replicate in a host and thus, will affect the level of virus
transmission. It has been shown that to achieve effectiveness of
antiviral treatment, therapy should be initiated within 48 hours of
the onset of clinical symptoms [11,12]. This is referred to as the
window of opportunity (WOP) [12,27]. It has also been shown that
a delay between the onset of symptoms and the initiation of therapy
can greatly affect the efficacy of treatment [28]. Early initiation of
treatment appears to be the most important determinant of
treatment efficacy [29]. Treatment started within the first 12 hours
aftertheonset of fevercanshorten the periodofillnessbymore than
3 days as compared with treatment started at 48 hours [29] and
treatmentinlaterstagesoftheWOPcanshortenthelengthofillness
proportionately [29]. Since early administration of drug decreases
the length of illness, we include two treated classes in the model:
early the WOP, late in the WOP, and after the WOP. This model is
similar to a previously published model by [28], but this model did
not divide the WOP into two stages and thus, did not capture the
effects of early versus late treatment.
We assume that viral transmission depends on the level of
treatment and the degree of symptoms demonstrated. We thus,
reduce the infectivity of the infected classes (asymptomatic,
symptomatic with no treatment, symptomatic and treated in the
first stage of the WOP, symptomatic and treated in the second
stage of the WOP) proportionately. We also assume that immunity
acquired from infection depends on the infected class. Thus, we
include four recovered classes which correspond to each infected
class. The resulting susceptible and recovered classes will be used
as the initial population for the second wave model.
The first wave model is used to explore two scenarios of school
closure. In the first scenario we assume that the first wave does not
coincide with summer school closure and thus, model the first
wave until the number of infections reaches zero (when the
number of susceptibles is depleted). In the second scenario we
consider the effects of summer school closure on the first wave.
This is done by reducing the transmission parameter to
correspond to a lower value of R0 (the basic reproduction ratio)
of the pandemic strain (see below).
First Wave Model. The first wave model considers a
population comprised of individuals that are susceptible (S),
exposed (E), asymptomatic infectious (A), untreated symptomatic
infectious (IU), early treated symptomatic infectious (IT1), late treated
symptomatic infectious (IT2), recovered from asymptomatic infection
(R1),recovered fromuntreated symptomaticinfection(R2),recovered
from early treated symptomatic infection (R3) and recovered from
late treated symptomatic infection (R4). The model is as follows:
Table 1. Antiviral stockpile size and number of doses of
vaccine by country.
Country stockpile # doses vaccine
Size vaccine uptake
(% population) (million) (% population)
Australia 41 21 30
Canada 25 50.4 40
China 1 100 3.2
France 50 94 7.8
UK 80 60 7
USA 30 195 20
doi:10.1371/journal.pone.0014307.t001
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represent the probability of infected individuals who remain
untreated until age a of clinical disease in the first and second
stages of the WOP and depend on the rates of treatment in these
stages, r1 and r2 respectively. Also,
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is the force of infection, where iT1, iT2, iU1 and iU2 are the
densities of treated and untreated individuals in the early and late
stages of the WOP, given by
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A schematic diagram for first wave model is depicted in Fig. 1.
Model parameters and descriptions are listed in Table 2 and
below. For the derivation of the model please see ‘‘Text S1’’. Note
that the recovered classes Ri’, i~1,2,3,4 are distinguished because
of different recovery rates from different infective classes and also
because these classes will have different levels of acquired
immunity which will affect the dynamics of the second wave.
Reproduction numbers. The basic reproduction number
(R0), defined as the number of new cases caused by one infectious
person entering a totally susceptible population (in the absence of
any interventions) [30], is the key parameter used to determine
whether an infection will spread in a population. For the first wave
model, we find that
R0~bS(0)
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z
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m
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where S(0) is the initial population of susceptibles. The three terms
correspond to the contributions of asymptomatic infectious
individuals and symptomatic infectious individuals during and
after the WOP.
The control reproduction number Rc is another useful quantity
that can be used to evaluate whether control measures or
interventions can contain or halt pathogen spread. For the first
wave model
Rc~bS(0)
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Note that, in absence of control measures (i.e. q(a)~q’(a):1)
Rc~R0.
Parameter Values. Parameter values for the first wave
model are listed in Table 2. Briefly, we assume that R0 is near
or in the reported range of 1:3{1:7 for the H1N1 pandemic [17–
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doi:10.1371/journal.pone.0014307.g001
Table 2. Population and parameters with description, values and sources for the 1st wave model.
Symbols Description Value Source
Populations
S Susceptible
E Exposed
A Asymptomatic
IU Symptomatic untreated
IT1 Symptomatic, treated day one of WOP
IT2 Symptomatic, treated day two of WOP
R1 Recovered from A
R2 Recovered from IU
R3 Recovered from IT1
R4 Recovered from IT2
Parameters
b Baseline transmission rate of infection variable with school closure b decreasing after 70 days
1=mE Mean incubation period 3 days [21,31]
1=mA Mean infectious period of asymptomatic infection 4.1 days [16]
1=mU Mean infectious period of untreated symptomatic infection 2.85 days [11,28]
1
 
mT1 Mean infectious period of symptomatic if treated
on day one WOP
1.05 days [28,42]
1
 
mT2 Mean infectious period of symptomatic if treated
on day two WOP
2 days [28,42]
n Length of the WOP 2 days [12,27]
dU Death rate of untreated symptomatic infection 0.002/day [28]
dT1 Death rate of symptomatic treated on day one of WOP 0.0001/day [28]
dT2 Death rate of symptomatic treated on day two of WOP 0.0002/day [28]
dA Relative infectiousness of asymptomatic infection 0.071 [28]
dU Relative infectiousness of untreated symptomatic infection 0.143 [28]
dT1 Relative infectiousness of treated (day one) symptomatic
infection
0.3 [28] and assumption
dT2 Relative infectiousness of treated (day two) symptomatic
infection
0.4 [28]
p Probability of developing symptoms 0.6 [11,16,22,24,31]
rmax Maximum treatment level in WOP 0.4
doi:10.1371/journal.pone.0014307.t002
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decrease the transmission paramter to reflect a lower R0, but keep
it such that R0w1. This was done in similar fashion to [9,10]. We
assume that after a short incubation period of 3 days [21,31] 60%
of infected individuals develop clinical symptoms [11,16,22,24,31]
and treatment may commence at this time. The mean infectious
period of symptomatic individuals who remain untreated is taken
to be 4.85 days [28,29] which includes the 2 day WOP [28,29]
and a mean duration of 2.85 days during which initiating
treatment is not effective. The mean duration of asymptomatic
infection is assumed to be 4.1 days [16] and antiviral treatment is
assumed to reduce infectiousness by 60% from the time when
treatment is initiated [11,32]. Asymptomatic infection is assumed
to be 50% less infectious than symptomatic cases [16]. The
baseline transmission rate is calculated using a final size relation
(see Text S1). The death rates of the symptomatic untreated and
treated classes are taken from [28].
To investigate the feasibility of containing a pandemic in the first
wave with antivirals, we prescribe five different scenarios for the
treatment rate (see Fig. 2).Weassume that treatment maycommence
with the onset of symptoms and it can be administered for 2 days (the
length of the WOP). We also assume that there is a maximum
treatment level rmax. Treatment profiles (i–iii) were chosen to reflect
the fact that antiviral stockpiles may be more limited in some
countries over others. In these three profiles the treatment rate
increases with slope a on the first day to the maximum level rmax.
This is then followed by either (i) a decline with slope {a on the
second day (Fig. 2(a)), (ii) a constant level at rmax on the second day
(Fig.2(b))or(iii)aconstantlevelofzero(Fig.2(c)).Treatmentprofile(i)
reflects a situation which gives priority to individuals that are
diagnosed in the mid-stages of the WOP. Treatment profile (ii)
reflects a situation in which a country may have a large stockpile and
can administer doses to individuals in the second stage of the WOP.
Treatment profile (iii) represents a scenario in which the stockpile is
limited, thus, antivirals are only given to individuals that present to
the doctors in the first stage of the WOP, which has a greater
probability of reducing infection and transmission. Treatment profiles
(iv–v) are similar to profiles (ii–iii), but have the same total treatment
rate (area under the curve) as profile (i) (see Fig. 2(d,e)). Profiles (iv–v)
may be chosen to replace profile (i) if they are more effective in
reducing infection and, perhaps, treat less infections. Treatment
profiles (i–v) can be represented by:
r1(a)~armax,0ƒaƒ1
r2(a)~(2{a)rmax,1ƒaƒ2
ð20Þ
Figure 2. Profile of treatment rate - function (i–v). r’max~2=3rmax and r’’max~2rmax.
doi:10.1371/journal.pone.0014307.g002
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We assume that the treatment of clinical cases commences only
after the first 30 days of the first wave. This reflects the fact that
there is usually a lag between the incidence of disease in a
population and clinical recognition of disease cases.
Second wave
Assumptions and Initial Conditions. Immunity gained
from infection in the first wave or vaccination will affect the
severity of the second wave. Firstly, it will change the overall
susceptibility of infection of the population, and secondly, it will
affect the number of cases that develop symptomatic infection. We
have developed a model of influenza transmission dynamics in the
second wave that includes susceptible classes that are delineated by
immune status from the first wave and by vaccination (see Table 3).
It is assumed that the susceptibility of each class with some existing
immunity will be reduced by factor c
i,i~1,2,3,4,5,( 0vc
iv1)
where c
2vc
5vc
4vc
3vc
1.
We include infected classes that are delineated by immune
status (si, i~1,2,3,4), (0vsiv1) at the time of exposure (see
Table 3). It is assumed that the development of symptomatic
infection is intimately linked to the immune status of the individual
at the time of exposure to the pathogen [25]. Thus, we assume that
the probability of asymptomatic infection increases by strength of
pre-existing immunity at the time of exposure. We take
s2ws4ws3ws1.
Second wave model. The effect of partial immunity on
seasonal influenza epidemics has been studied through history-
based formulations [33–35] and status-based models [36,37]. We
propose a second wave model that is related to these models in that
it includes reduced susceptibility of a susceptible host population
and reduced transmissibility of infected individuals. The model is an
extension of the classical SIR model [38] and can be written as
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where c ~1, r
i is the probability of symptomatic infection,
nj,j~1,2,3,4 are the recovery rates of respective classes of infected
individuals and w
1,w
2 are the proportion of symptomatic infected
individuals initiating treatment on the first and second stages of the
WOP respectively.
If S~
P5
i~ ,1 qi, I~
P4
j~1 pj and R~r and c
i~c,Vi, sj~s
and nj~n, Vj then the above model reduces to the SIR model
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where bsc*b. A schematic of the second wave model is shown in
Fig. 3. Parameters and descriptions are listed in Table 3 and
below. Note that the we chose not to employ a similar model to
Eq. 10 for the second wave since vaccination would dominate the
infection outcomes and, thus the effects of the different treatment
profiles in the second wave would be negligible.
Reproduction numbers. The number of secondary cases in
the second wave is given by the control reproduction number
Rc~Rc,1Prob1zRc,2Prob2zRc,3Prob3zRc,4Prob4 ð34Þ
where
Rc,1~
bs1
n1
X 5
i~ ,1
c
iqi
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which give the number of secondary infections produced by an
infected individuals that is asymptomatic, symptomatic and
untreated, symptomatic and treated on the first stage of the
WOP and symptomatic and treated on the second stage of the
Table 3. Population and parameters with description, values and sources for the 2nd wave model.
Symbols Description Value Source
Populations
q  Not infected in the first wave
q1 Recovered from asymptomatic infection in first wave
q2 Recovered from symptomatic untreated infection
in first wave
q3 Recovered from treated symptomatic infection
on day one of WOP in first wave
q4 Recovered from treated symptomatic infection on
day two of WOP in first wave
q5 Vaccinated at beginning of second wave
p1 Asymptomatic infected in second wave
p2 Symptomatic infected and untreated in second wave
p3 Symptomatic infected and treated on day one of
WOP in second wave
p4 Symptomatic infected and treated on day two of WOP
in second wave
Parameters
b transmission rate in the second wave 0.9302 and 1.0148 when no school closure in the first wave
0.6342 when school closure is considered in the
first wave
c1 Reduction in susceptibility of q1 0.75 Assumption
c2 Reduction in susceptibility of q2 0.25 Assumption
c3 Reduction in susceptibility of q3 0.5 Assumption
c4 Reduction in susceptibility of q4 0.4 Assumption
c5 Reduction in susceptibility of q5 0.3 Assumption
r  Probability of symptomatic infection of q  0.6 Assumption
r1 Probability of symptomatic infection of q1 0.5 Assumption
r2 Probability of symptomatic infection of q2 0.2 Assumption
r3 Probability of symptomatic infection of q3 0.4 Assumption
r4 Probability of symptomatic infection of q4 0.3 Assumption
r5 Probability of symptomatic infection of q5 0.25 Assumption
s1 Reduction in infectiousness of p1 0.2 Assumption
s2 Reduction in infectiousness of p2 0.7 Assumption
s3 Reduction in infectiousness of p3 0.3 Assumption
s4 Reduction in infectiousness of p3 0.4 Assumption
1=n1 Mean infectious period of p1 4.1 days [16]
1=n2 Mean infectious period of p2 4.85 days [11,28]
1=n3 Mean infectious period of p3 3.05 days
1=n4 Mean infectious period of p4 4 days
w1 Probability of treatment on day one of WOP Variable
w2 Probability of treatment on day two of WOP Variable
doi:10.1371/journal.pone.0014307.t003
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are the probabilities of infection being initiated by an individual
that is asymptomatic, symptomatic and untreated, symptomatic
and treated on the first stage of the WOP or symptomatic and
treated on the second stage of the WOP.
In the absence of vaccination and antiviral treatment in the
second wave Rc reduces to the effective reproduction number
Re~
bs1
n1
X 4
i~ ,1
(1{r
i)c
iqiz
bs2
n2
X 4
i~ ,1
r
ic
iqi ð35Þ
and if no prior immunity against the pathogen exists it further
reduces to the basic reproduction number
R0~
(1{r)bs1
n1
z
rbs2
n2
: ð36Þ
Parameter values. Parameter values are similar to those
used in the first wave and were taken from the modelling and
clinical literature of influenza A and H1N1. When we do not
consider the effects of summer school closure we assume that R0 in
the second wave is greater than R0 for the first wave so that
infection of the population with partial immunity will still occur
(Rew1). This reflects the fact that in some pandemic situations the
second wave may be started by an imported case of a mutated and
higher fit strain than what was present during the first wave of a
pandemic. Here, we have chosen to study R0w2 such that Rew1.
When summer school closure is considered, we increase the
transmission rate back up to the value used in the beginning of the
first wave when schools are openned for the next school term. This
reflects the fact that social contacts are increased when school
returns. We also chose values for reduced susceptibility and
symptomatic infection so that the relationships c
2vc
5vc
4vc
3
vc
1 and s2ws4ws3ws1 are satisfied.
The initial population of the second wave will depend on the
treatment profile of the first wave (see Results). It is assumed that
the same proportion of the resulting susceptible and recovered
classes from the first wave are vaccinated.
Results
We consider two scenarios of school closure. We first consider
the case when the pandemic occurs at a time when summer school
closure will not coincide with the first or second wave. We then
consider the case when summer school closure occurs during the
first wave of infection similar to that experienced in the 2009
H1N1 pandemic. In both scenarios we first simulate the first wave
model Eq. 10 to evaluate the impact of different treatment profiles
on disease incidence. We then simulate both models, using the
results of the first wave model to initialize the second wave model
Eq. 30 to compare and contrast different combinations of
treatment and vaccination strategies.
No school closure in the first wave
First wave. Fig. 4(a,b) shows the progression of infection in a
population and the cumulative attack rate (untreated and treated
infections) over the first wave when R0~1:6 for each treatment
profile ((i) - blue, (ii) - red, (iii) - green, (iv) - pink and (v) - yellow)
and when treatment is not used (black). When treatment is not
used, the first wave infection peaks at 1.3% of the population
around day 60–70 and 38% of the population experiences
infection over the whole wave. As the treatment rate increases
the wave peak decreases in magnitude and occurs later in time
Fig. 4(a). The cumulative attack rate also decreases Fig. 4(b).
As R0 increases, the wave peak increases (not shown) and the
proportion of the population experiencing infection also increases
with and without treatment (Fig. 4(c)). When treatment is used, the
cumulative attack rate is greatly reduced (Fig. 4(c)). When R0 is
only slightly greater than one the five treatment profiles result in a
similar number of total infections (Fig. 4(c)). However, as R0
increases they diverge but follow similar dynamics: there will be a
steep increase in the number of infections and this will be followed
by an approximately linear relationship with R0 (Fig. 4(c)).
The distribution of the susceptible and recovered classes at the
end of the first wave depends on the value of R0 (not shown) and
also on the treatment profile used (Fig. 4(d) assuming R0~1:6).
The proportion of the population receiving treatment is also
affected i.e. if R0~1:6, 7.7, 6.1, 4.9, 7.3 and 5.6% of the
population received some form of treatment under treatment
profiles (i–v) respectively (Fig. 4(d)). The resulting distribution will
provide the starting population of the second wave.
Comparing the different treatment profiles we see that profile (ii)
always results in the lowest amount of infection. The overall
treatment efficacy however, may not be the best. When R0~1:6
over 50% of those treated under treatment profile (ii) received drug
Figure 3. Schematic diagram of second wave model.
doi:10.1371/journal.pone.0014307.g003
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less effective at reducing disease and transmission. In contrast,
treatment profile (v) which results in only a slightly higher level of
infection (Fig. 4(b,c)) uses less drugs and all those treated were
given treatment on the first day (Fig. 4(d)).
Second wave. It is not known what the basic reproductive
ratio of the second wave of a pandemic will be and it cannot be
measured since partial immunity in the population exists. It is
possible that the second wave will be initiated by a more fit
strain of H1N1 in that the transmission rate increases. It is also
possible that the virus will have evolved so that individuals that
were infected in the first wave are not fully immune. In this
section we have chosen values for the transmission rate b so that
Rew1 for the initial population resulting from any of the five
treatment profiles in the first wave and when vaccination is used
at the start of the second wave. It is assumed that, when
vaccination is used, the same proportion of individuals from
each susceptible class will be vaccinated. The Re values are
1:3685 and 1:6705, 1:8843, 1:5803, 1:6991, 1:8140 correspond-
i n gt on ot r e a t m e n ta n du s i n gt r e a t m ent profile (i–v) respectively
when b~0:9302 in the second wave. We also look at a second
case for a more fit strain with b~1:0148, the respective values
of Re are 1:4929 and 1:8224, 2:0556, 1:7239, 1:8536, 1:9789.
In this section we have also chosen values for ci and ri,
i~   ,1,2,3,4 to reflect reduced levels of susceptibility and a
reduced probability of symptomatic infection depending on the
infection history in the first wave.
Second wave without vaccination - Fig. 5(a) (black line) shows
the case when drug therapy and vaccination are not used during
the first and second waves when b~0:9302 (left) and b~1:0148
(right). Comparing the first and second waves (Fig. 4(a) and
Fig. 5(a)) we see that the peak is decreased in the second wave and
it occurs at a later time. The cumulative attack rate is also lower
(Fig. 4(b) and Fig. 5(a)).
When drug therapy is used in the first wave, the second wave is
more severe (Fig. 5(a) coloured lines) compared to when it is not
(Fig. 5(a) black line). The wave peak is higher and occurs earlier in
time. The cumulative attack rate is also greater. Thus, drug
therapy interventions in the first wave have a substantial impact on
the second wave. This is a direct effect from the difference in the
underlying immunity of the susceptible population at the
beginning of the second wave.
In Fig. 5(b,c) we show the prevalence of infection and
cumulative attack rate in the second wave when b~0:9302 (left)
and b~1:0148 (right) when drug therapy is used to treat infected
individuals in the second wave. Fig. 5(b) reflects the scenario when
the antiviral stockpile is limited and Fig. 5(c) reflects the situation
when a large antiviral stockpile exists. The prevalence of infection
and the cumulative attack rate is reduced when drug therapy use
increases. However, if b~0:9302 and drug uptake is v5%
(Fig. 5(b), left) the magnitude of the second wave is similar to the
case when b~1:0148 and drug uptake is w5% (Fig. 5(c), right).
Note that, if drug therapy is used in the first wave, profile (iii)
always results in the lowest number of infections whether drug
therapy is used in the second wave or not.
Second wave with vaccination - Vaccination affects the severity
of the second wave of infections. When only vaccination is used the
peak of the second wave is reduced in magnitude and occurs later
Figure 4. First wave with and without treatment with no school closure. (a) Disease incidence with no treatment (black line) and with
treatment profiles (i–v) (blue, red, green, pink, yellow) when R0~1:6. (b) Cumulative attack rate under no treatment and treatment with profiles (i–v)
when R0~1:6. For each profile of treatment the cumulative value at the end point corresponds to the clinical attack rate given by p(1{S(?)=S(0)),
where p,S(?),S(0) respectively gives the probability of getting symptoms, the final value of susceptible at the end of epidemic and the initial
susceptible population in the beginning. (c) Cumulative number of infections with no treatment and treatment profiles (i–v) when 1:1ƒR0ƒ1:8. (d)
Distribution of resulting susceptible and recovered classes from first wave for no treatment and treatment profiles (i–v).
doi:10.1371/journal.pone.0014307.g004
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(Fig. 6(a) and Fig. 5(a)). In turn, it reduces the cumulative attack
rate in the second wave (Fig. 6(a) and Fig. (5a)). When both
vaccination and drug therapy is available in the second wave these
are also further reduced (Fig. 6(b,c) and Fig. 5(b,c)). When
b~0:9302 and drug uptake is w5% (Fig. 6(c) left) the second wave
is almost non-existent for the case when drug therapy is not used in
the first wave (black line). Note that, if drug therapy is used in the
first wave, profile (iii) always results in the lowest number of
infections whether drug therapy is used in the second wave or not.
Fig. 7 plots the combined effect of antiviral treatment and initial
vaccination in reducing the control reproduction number Rc in the
second wave for treatment profiles (i) and (iii) when Re~1:6705
and Re~1:5803 corresponding to b~0:9302 in the second wave.
This figure shows that as vaccination uptake increases, the need
for drug therapy to control infection in the second wave reduces.
Also, when drug therapy use increases, the need for vaccination to
control the second wave decreases. This is true for all treatment
profiles used in the first wave, however, treatment profile (iii)
results in a distribution of susceptibles of the second wave that is
more sensitive to the effects of vaccination and drug therapy
uptake in the second wave.
Vaccination may not be available at the beginning of the second
wave. A delay of up to 40 days in the release of the vaccine will
have little to no effect on the second wave peak and on the
cumulative attack rate (Fig. 8 for treatment profile (v) in the first
wave). This is true for all treatment profiles (not shown).
Both waves. The goal of a pandemic control strategy is
ultimately to reduce the total level of infection. Fig. 9 shows the
cumulative number of infections (asymptomatic, symptomatic
untreated and symptomatic treated on either day) over both waves
for all treatment profiles in the first wave, and all combinations of
drug therapy and vaccination in the second wave. This figure
shows that the cumulative number of cases will lie between
50{100% of the population depending on the control strategy in
both waves.
Figure 5. Disease incidence in second wave without vaccine and no school closure in first wave. Clinical infection in second wave with no
vaccine when b~0:9302 (left) and b~1:0148 (right) having no school closure in the first wave. Lines correspond to no treatment (black) or treatment
following profile (i–v) (blue, red, green, pink, yellow) in the first wave when R0~1:5. In each plot disease incidence and cumulative attack rates are
shown. (a) No drug or vaccine. (b) With drug but no vaccine. Drug uptake is v5%. (c) With drug but no vaccine. Drug uptake is w5%.
doi:10.1371/journal.pone.0014307.g005
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second wave (Table 4(a) with R0~1:5, in the first wave and
b~0:9302 in the second wave), we find that a control strategy of
vaccination and high use of drug therapy in the second wave will
always result in the lowest number of cases no matter what
treatment profile is used in the first wave. The lowest level of
infection over both waves, &54:5% of the population, results from
a combination of treatment profile (iii) in the first wave and
vaccination and w5% drug uptake in the second wave. However,
if drug therapy uptake in the second wave is low or vaccination is
not available in the second wave, then the best strategy to
minimize the total number of infections over both waves is to use
no drug therapy in the first wave. If both vaccination and drug
therapy are not available in the second wave, profile (ii) in the first
wave results in the lowest number of total infections.
All infections are not visible to public health as some may be
asymptomatic. Table 4(b) lists the cumulative number of clinical
cases (treated and untreated, cumulative attack rate) over both
waves assuming R0~1:5 in the first wave and b~0:9302 in the
second wave. To reduce the total number of clinical cases
treatment profile (iii) in the first wave along with vaccination and
w5% drug uptake in the second wave still results in the lowest
number. Also, if drug uptake is low in the second wave, or if
vaccination is not available in the second wave, then no treatment
in the first wave still results in the lowest number, and profile (ii) in
the first wave will result in the lowest number of clinical cases if
there is no vaccination or drug available in the second wave.
If the vaccination level is lower than 30% uptake in the second
wave, then no treatment in the first wave may result in a lower
number of infections than treatment profile (iii) when vaccination
and drug therapy (w5%) are available in the second wave (not
shown). Also, profile (ii) may replace no treatment in the first wave
as the best strategy if vaccination uptake is low when drug therapy
uptake is v5% in the second wave (not shown). In both of these
cases, however, the difference between no treatment and profile
(iii), and no treatment and profile (ii) is very small (not shown).
Figure 6. Disease incidence in second wave with vaccine and no school closure in first wave. Clinical infection in second wave with
vaccine when b~0:9302 (left) and b~1:0148 (right) having no school closure in the first wave. Lines correspond to no treatment (black) or treatment
following profile (i–v) (blue, red, green, pink, yellow) in the first wave when R0~1:5. In each plot disease incidence and cumulative attack rates are
shown. (a) With vaccine but no drug. (b) With drug and vaccine. Drug uptake is v5%. (c) With drug and vaccine. Drug uptake is w5%.
doi:10.1371/journal.pone.0014307.g006
Influenza Pandemic Mitigation
PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e14307School closure in the first wave
School closure during the summer vacation may result in a
reduction in transmissibility of H1N1 in the first wave [9]. The
closing of schools over the summer months will reduce the number
of contacts of school age children, thus affecting the transmissi-
bility of the H1N1 pandemic virus which may cause a great
decrease in infections. This could be seen as the first wave of the
pandemic. In this section school holidays are assumed to start 70
days after the first wave emerges and last approximately 60 days
(July and August). This gives a total duration of 130 days of first
wave of the pandemic (starting from last week of April). The
second wave is considered for 180 days (from September to
February of the next year). As before, we simulate the first wave
model to evaluate the different treatment profiles on disease
burden and then we simulate both models using the resulting
distribution of the susceptible and recovered populations at the
end of the first wave.
First wave. As the contact pattern changes due to school
closure approximately 70 days after the first wave emerges, we
assume that the transmissibility of the virus reduces by 30%
(b~0:6733) of the initial transmissibility (R0~1:5 initially) [10].
Fig. 10(a) shows that if there is no treatment the first wave infection
peaks at 0.8% of the population around day 70 and it comes down
as the transmissibility reduces observably during the summer
holidays. Approximately 21% of the population experiences
infection over the whole wave without treatment (Fig. 10(b)).
Treatment with the different profiles (i–v) reduces the wave peak in
magnitude (Fig. 10(a)). The cumulative attack rate also decreases
accordingly due to treatment in the school closure scenario
(Fig. 10(b)). Note that total infection is greatly reduced in this
scenario when compared to the case when school closure does not
occur.
Fig. 10(c) shows the distribution of the susceptible and recovered
populations for all scenarios of treatment in the first wave (i–v).
This figures demonstrates that school closure over the summer
months increases the naive susceptible population to levels close to
100% (93.1, 97.6, 88.6, 94.4 and 96.8% for profile (i–v)
respectively) for second wave. For treatment profiles (i–v), 1.3,
0.6, 1.2, 1.2 and 0.6% of the population received some form of
treatment respectively (Fig. 10(c)). The distribution of the
susceptible and recovered populations from the first wave provides
the starting population at the beginning of the second wave, when
schools reopen for the next school year.
Second wave. In the 2009 H1N1 pandemic the first dip of
infection (or first wave) was probably caused by the end of
the school term [9]. However, when school returns the
transmissibility which was reduced during summer vacation can
then be restored to its original value in the second wave. In the
second wave we find that the Re values are 1:1703 and
1:4366,1:4779,1:3926,1:4482,1:4709 corresponding to no treat-
ment and using treatment profile (i–v) where the minimum is with
profile (iii) and the maximum is with profile (ii) when treatment is
considered. As before, we assume that the same proportin of
individuals from each susceptible class is vaccinated.
Second wave without vaccination - Fig. 11 shows the level of
infection (left) and cumulative attack rate (right) over the first
180 days of the second wave when vaccination is not used as a
control strategy in the second wave. This figure demonstrates
Figure 7. Combined effect of antiviral and vaccine during second wave with no school closure in first wave. The combined effect of
antiviral treatment and initial vaccination in reducing the control reproduction number (Rc) during the second wave of the pandemic with b~0:9302
(left) and b~1:0148 (right) having no school closure in the first wave. The white region shows the eradication of the disease where the grey region
shows disease persistence. (a) Profile (i) used in first wave. (b) Profile (iii) used in first wave.
doi:10.1371/journal.pone.0014307.g007
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results in the lowest number of infections in the second wave by
a considerable margin. This is true when treatment is not used
in the second wave (Fig. 11(a)), treatment levels are low
(Fig. 11(b)) and when treatment levels are high (Fig. 11(c)).
Thus, when drug therapy is used in the first wave, the severity of
t h es e c o n dw a v ei sg r e a t l yi n c r eased. This is similar to the
situation observed without school closure. Note that school
c l o s u r em a k e sp r o f i l e( i i )a n dp r o f i l e( v )h a v ea l m o s tt h es a m e
effect on the attack rate whether there is use of drug or not in
the second wave.
Second wave with vaccination - Vaccination gives the same
qualitative features as it did when school closure was not
considered. When only vaccination is used the peak of the second
wave is reduced in magnitude and occurs later in time compared
to the case when only drug therapy is used (Fig. 11(a) and
Fig. 12(a)). In turn, it reduces the cumulative attack rate in the
second wave (Fig. 12(a) (right). When drug therapy and vaccine are
both used in the second wave the total level of infection and
cumulative attack rate are also reduced when compared to the
case when vaccination was not used in the second wave (Fig. 11(b,c)
and Fig. 12(b,c)).
The second wave is almost non-existent when drug therapy is
not used in the first wave (Fig. 12(a,b,c)). If drug therapy is used in
the first wave profile (iii) results in the lowest level of infection in
the second wave(Fig. 12(a,b,c) green line). This is also true when
school closure is not considered (Fig. 6, green line).
Both waves. The cumulative number of infections
(asymptomatic, symptomatic untreated and symptomatic treated
on either day) over both waves for all treatment profiles in the first
wave, and all combinations of drug therapy and vaccination in the
second wave is shown in Fig. 13. This figure shows that the
reduced transmissibility due to school closure over the summer
months during the first wave reduces the total cumulative number
over both waves when compared to the case when school closure
did not occur (Fig. 9 and Fig. 13). The total cumulative infections
when school closure occurs lies between 8{60% of the population
depending on the control strategies used in both waves.
Figure 8. Delaying vaccination in second wave with no school closure in first wave. Effect of delay in initiating vaccination for second wave
of clinical infection when b~0:9302 (left) and b~1:0148 (right) having no school closure in the first wave. Lines correspond to 0, 10, 20, 30 and 40
days delay. Initial distribution results from profile (v) in the first wave when R0~1:5. In each plot disease incidence and cumulative infections are
shown. (a) With vaccine but no drug. (b) With drug and vaccine. Drug uptake is v5%. (c) With drug and vaccine. Drug uptake is w5%.
doi:10.1371/journal.pone.0014307.g008
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waves, we find that a control strategy of vaccination and a high use
of drug therapy in the second wave will always result in the lowest
number of cases no matter what treatment profile is used in the
first wave (Table 5(a)). This is also the case when school closure
was not considered. However, the lowest number of total
infections when considering school closure results from a
combination of treatment profile (ii) in the first wave and
vaccination and w5% drug uptake in the second wave. This
differs from our previous result where treatment profile (iii) in the
first wave and vaccination and w5% drug uptake in the second
wave resulted in the lowest number of cases. Note that in all
scenarios profile (iii) results in a higher number of infections than
profile either or both of profile (iv) or (v). Thus, using treatment
profile (iii) should not be considered if school closure over the
summer months coincides with the first wave of infection.
When vaccination is used in the second wave, or when
vaccination is not used and drug therapy is high in the second
wave, profile (ii) results in the lowest level of total infection
(Table 5(a)). However, when vaccination is not used in the second
wave and drug therapy use during the second wave is low or
nonexistent then no treatment in the first wave results in the lowest
cumulative number of infections over both waves (Table 5(a)).
Table 5(b) gives the cumulative number of clinical cases (treated
and untreated) over both waves. The results here are the same as
in that found for (Table 5(a)).
Discussion
Pandemic preparedness is a public health priority and, with the
recent emergence of the highly pathogenic H1N1 influenza virus,
it has become even more important to define control policies that
Figure 9. Cumulative total infections in both waves with no school closure in first wave. Cumulative infections (clinical and subclinical) in
both waves when R0~1:5 in the first wave having no school closure. The five panels correspond to second wave: (a) no drug or vaccine (solid line),
(b) no vaccine with drug v5% (dashed line), (c) no vaccine with drug w5% (dashdot line), (d) with drug uptake v5% and vaccine coverage 30%
(dotted line), (e) with drug uptake w5% and vaccine coverage 30% (solid line with circles). In each panel lines correspond to no treatment (black) and
treatment profile (i–v) (blue, red, green, pink, yellow) in the first wave.
doi:10.1371/journal.pone.0014307.g009
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greatly reduce the number of infections and the burden on the
health care system. The control policy that a particular country
may adapt will depend greatly on the resources of that country
and, perhaps, on the generousity of other countries. Thus, the
control policy that is adapted will differ between countries with
high or low levels of antiviral stockpiles, and high or low levels of
vaccine doses being purchased. The efficacy of the control policy
Table 4. Cumulative (a) total infections and (b) clinical cases over both waves when R0~1:5 in first wave without school closure
and b~0:9302 in the second wave.
Second wave
no drug v5% w5% v5% w5%
no vaccine no vaccine no vaccine 30% 30%
(a) First wave no treatment 96.7 86.7 66.2 58.4 58.3
profile (i) 99.4 92.3 83.0 76.4 64.3
profile (ii) 94.1 88.2 80.3 74.7 65.8
profile (iii) 99.6 92.0 82.1 74.0 54.5
profile (iv) 98.5 91.6 82.5 76.1 65.0
profile (v) 96.3 90.0 81.7 75.9 66.5
(b) First wave no treatment 54.6 49.6 39.1 35.0 35.0
profile (i) 56.2 52.5 47.5 43.2 36.9
profile (ii) 54.1 50.9 46.5 42.3 37.5
profile (iii) 56.2 52.3 47.0 42.1 32.0
profile (iv) 55.8 52.1 47.2 42.9 37.2
profile (v) 55.1 51.7 47.1 43.0 37.9
doi:10.1371/journal.pone.0014307.t004
Figure 10. Disease incidence in first wave with and without treatment and school closure for last 60 days. First wave with and without
treatment considering school closure in the first wave from the day 71 to day 130. (a) Disease incidence with no treatment (black line) and with
treatment profiles (i–v) (blue, red, green, pink, yellow) when R0~1:5. (b) Cumulative attack rate under no treatment and treatment with profiles (i–v)
when R0~1:5. For each profile of treatment the cumulative value at the end point corresponds to the clinical attack rate. (c) Distribution of resulting
susceptible and recovered classes from first wave for no treatment and treatment profiles (i–v).
doi:10.1371/journal.pone.0014307.g010
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of these antivirals, the rate of uptake of antiviral drugs
(presentation to a doctor), the distribution of the vaccine and
vaccine uptake. The efficacy of a control policy will also depend on
the circulating strain, especially in successive waves since
individuals infected in previous waves will have acquired some
immunity.
A number of epidemiological models have explored various
mitigation strategies for pandemic influenza throughout the globe.
However, with the exception of [9] these have focussed on a single
wave of infection. We developed a model that describes the first
and second wave of an influenza pandemic which includes the two
major interventions that can be taken during a pandemic,
antivirals and vaccination. The model was used to assess the
impact of different combinations of these on the severity of the first
and second waves, and on the total number of infections over both
waves for two scenarios when the first wave coincides with school
closure over the summer months and when it does not. The first
wave model includes the use of antiviral, where antivirals are not
used, or one of five different treatment profiles is used. Each
scenario was chosen to reflect possible use of countries with no
antiviral stockpile (so no use of antivirals), a small stockpile (profile
(iii)), a medium sized one (profile (i)), or a very large one (profile
(ii)). We also explored the effects of changing treatment profile (i) to
similar profiles of (ii) and (iii) where the total probability of
treatment over the WOP was the same (treatment profiles (iv–v)).
The outcome of the first wave is a susceptible population that has
varying degrees of immunity gained from infection. This
population is used as the initial population of the second wave
of infection. In the second wave model we explored different
combinations of drug treatment rates and vaccination uptake on
the level of infection, including the effects of prior immunity from
the first wave. This was done for two different values of of
transmission b, when school closure was not considered so as to
Figure 11. Disease incidence in second wave without vaccination and with school closure in first wave. Clinical infection in second wave
with no vaccine (left) and corresponding cumulative attack rate (right) when R0~1:5 in the first wave with school closure. Lines correspond to no
treatment (black) or treatment following profile (i–v) (blue, red, green, pink, yellow) in the first wave when R0~1:5. (a) No drug or vaccine. (b) With
drug but no vaccine. Drug uptake is v5%. (c) With drug but no vaccine. Drug uptake is w5%.
doi:10.1371/journal.pone.0014307.g011
Influenza Pandemic Mitigation
PLoS ONE | www.plosone.org 16 December 2010 | Volume 5 | Issue 12 | e14307capture the possibility of more fit influenza strains in the second
wave.
We find that no matter what treatment strategy is used in the
first wave, a combination of vaccination and w5% drug uptake in
the second wave will result in the lowest amount of infection and
clinical cases. This is lowest when treatment profile (iii) is used in
the first wave when school closure is not considered and it is lowest
when treatment profile (ii) is used in the first wave when summer
school closure is included in the model.
In cases where vaccination and drug therapy are not readily
available the optimal treatment strategy changes. When school
closure is not considered the model predicts that if drug uptake is
low in the second wave and vaccination is available, the total
number of infections and clinical cases will be reduced if no drug
therapy is used in the first wave. This result is also found in cases
where drug therapy is available in the second wave but vaccination
is not. However, if neither drug therapy or vaccination is available
in the second wave, then treatment profile (ii) in the first wave will
result in the lowest number of infections and clinical cases. The
results vary when schools are closed over the summer months.
Here, the model predicts that profile (ii) in the first wave will result
in the lowest number of infections in all cases except when
vaccination is not availble in the second wave and drug therapy
use is low or non-existent.
Though the cost-effectiveness analysis of the proposed mitigation
strategies has not been explicitly included in the present model, it is
assumed that this is related to the total number of infections and
clinical cases(Fig. 9,13and Table 4,5).Theeconomic evaluation of
inter-pandemicinfluenzaprogramsisanimportantissueinaspectof
pandemic preparedness and our model could be compared with the
economic evaluation of mitigation strategies from a social
perspective in the USA [39] and Europe [9].
Though the parameter values introduced to reflect a reduction
in susceptibility, a reduction in infectiousness and the probability
Figure 12. Disease incidence in second wave with vaccination and with school closure in first wave. Clinical infection in second wave
with vaccine (left) and corresponding cumulative attack rate (right) when R0~1:5 in the first wave with school closure. Lines correspond to no
treatment (black) or treatment following profile (i–v) (blue, red, green, pink, yellow) in the first wave when R0~1:5. (a) With vaccine but no drug. (b)
With drug and vaccine. Drug uptake is v5%. (c) With drug and vaccine. Drug uptake is w5%.
doi:10.1371/journal.pone.0014307.g012
Influenza Pandemic Mitigation
PLoS ONE | www.plosone.org 17 December 2010 | Volume 5 | Issue 12 | e14307of symptomatic infection in the second wave model are to some
extent based on assumptions underlying the model, we conceive
that the model results are significant and will aid in future
directions in policy making for pandemic preparedness. In this
context, however, more detailed model validation and parameter
estimation using data from the current H1N1 pandemic or past
pandemics should be a priority for future work. In the context of
pre-existing immunity our results could be reviewed with some
other modelling of mitigation strategies where it was predicted that
pre-existing immunity in 15% or more of the population kept the
attack rates low even if the whole population was not vaccinated or
vaccination was delayed [22].
Immuno-epidemiology is an emerging field which studies the
effects of individual immunity on disease dynamics at the
population level. Recently, Heffernan and Keeling [25,40] used
a model describing the pathogenesis of measles in-host to
parameterize an epidemiological model of measles infection to
study the effects of vaccination and waning immunity on disease
prevalence and asymptomatic infections. A similar study for
influenza would be helpful in determining the level of immunity
gained after influenza infection, studying how partial immunity
aids in the protection of an individual against future strains of
influenza, and studying how different distributions of pre-existing
immunity from previous infection or vaccination in a population
may provide herd immunity.
Future extensions of our model can include the study of the
effects of other non-pharmaceutical intervention strategies on the
severity of the first and second waves of a pandemic. These can
include other scenarios of school closure that were not considered
here, case isolation, household quarantine and restrictions on
travel. However, the inclusion of one or more of these intervention
strategies will add greatly to the complexity of the model.
Figure 13. Cumulative total infections in both waves with school closure in first wave. Cumulative infections (clinical and subclinical) in
both waves when R0~1:5 in the first wave with school closure. The five panels correspond to second wave: (a) no drug or vaccine (solid line), (b) no
vaccine with drug v5% (dashed line), (c) no vaccine with drug w5% (dashdot line), (d) with drug uptake v5% and vaccine coverage 30% (dotted
line), (e) with drug uptake w5% and vaccine coverage 30% (solid line with circles). In each panel lines correspond to no treatment (black) and
treatment profile (i–v) (blue, red, green, pink, yellow) in the first wave.
doi:10.1371/journal.pone.0014307.g013
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study, but with the consideration of a higher R0 in the second wave
we do account for the better strain fitness that is able to overcome
some of the immunity gained from previous infection or vaccination.
Previous modeling studies on the effects of the accumulation of drug
resistant mutations have, like our study, found that use of drug
therapies should be minimized so as to prevent large epidemics
where drug therapy has no effect [24,41–43].
In conclusion, the two wave model predicted that if drug
therapy is readily available and a vaccine is available in the second
wave, then profile (iii) or (ii) combined with this will result in the
lowest number of possible infections in the population. However,
the use of no treatment in the first wave is optimal in most cases
when the drug therapy stockpile is limited, drug therapy use is low
and if vaccination is not available. These results pertain to the
population setting. The best result for an individual in the
population is to prevent or stave off severe infection. In future
work the benefits of the individual against the population will be
weighed. This may affect the level of drug therapy use predicted
by the model.
Supporting Information
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